# Clinical Study of UCB Combined With UC-MSCs in the Treatment of Bone Marrow Failure Disorders

> **NCT05794425** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shandong Qilu Stem Cells Engineering Co., Ltd.** · enrollment: 100 (estimated)

## Conditions studied

- Bone Marrow Failure Disorders

## Interventions

- **DRUG:** Cyclosporine A
- **BIOLOGICAL:** Umbilical cord blood & Umbilical cord derived mesenchymal stem cells

## Key facts

- **NCT ID:** NCT05794425
- **Lead sponsor:** Shandong Qilu Stem Cells Engineering Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-08-01
- **Primary completion:** 2025-04
- **Final completion:** 2026-04
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2023-11-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05794425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05794425, "Clinical Study of UCB Combined With UC-MSCs in the Treatment of Bone Marrow Failure Disorders". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05794425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*